Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (221)	6/13/2001 4:13:57 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 273

Hi David: Funny, I was thinking today that if oxygn has bad news I'm dead since there was only 100 shares traded in the first couple of HOURS. Given my market power I rarely have trouble executing market orders if necessary, but a 1000 share market sell may put oxgn at risk of delisting. Yes, I still own a less-than-full-more-than-token position in DNDN which I will hold or fold depending on the prostate results. I was unable (by that I mean I was incapable) to really determine if the patients in PIII will be identical to the PII published patients, but I found some assurance (from the company) about the change in the pre-treatment antigen test. So I'm reasonably hopeful that results will be duplicated--if so, I really like the platform nature of their antigen shuffling and dendritic coupling even if it is not the most robust system reported. Since you ask, have you heard anything I can obsess about, productively or not? Wilder